This partnership will allow users of the Eversense device to view real-time glucose levels and associated data in Glooko’s mobile and web apps.
Healthcare professionals will also be able to view this data in Glooko’s population tracker reports.
Senseonics president and CEO Tim Goodnow said: “With personalised medicine at the forefront of healthcare, data integration between Eversense CGM and Glooko helps provide customised data for users, as well as healthcare providers.
“We believe this information can empower our community to help manage their diabetes with new insights and actions and, ultimately, improve lives.”
The Eversense CGM device comprises a fluorescence-based sensor that is injected into the arm. This communicates with a smart transmitter, which sends data to the accompanying mobile app that displays glucose values, trends and notifications.
The smart transmitter is designed to deliver discreet on-body vibratory alerts to users in case of high and low glucose levels.
Glooko CEO Russ Johannesson said: “Eversense is an innovative solution for making glucose data more accessible, and we feel users will get tremendous value out of seeing this data correlated with food, activity, and medication information they log in Glooko to help them make treatment decisions.”
Glooko formed a similar alliance in October last year to support the integration of dosing data from Novo Nordisk ‘s connected insulin pens into its diabetes management solution.